Strs Ohio Purchases Shares of 12,200 Mirum Pharmaceuticals, Inc. $MIRM

Strs Ohio purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,200 shares of the company’s stock, valued at approximately $550,000.

Several other institutional investors and hedge funds have also recently modified their holdings of MIRM. Vanguard Group Inc. increased its stake in Mirum Pharmaceuticals by 4.8% in the first quarter. Vanguard Group Inc. now owns 2,540,061 shares of the company’s stock valued at $114,430,000 after acquiring an additional 115,327 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Mirum Pharmaceuticals by 4,555.0% during the first quarter. GAMMA Investing LLC now owns 5,586 shares of the company’s stock valued at $252,000 after buying an additional 5,466 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Mirum Pharmaceuticals by 174.9% during the first quarter. SG Americas Securities LLC now owns 19,182 shares of the company’s stock valued at $864,000 after buying an additional 12,204 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Mirum Pharmaceuticals by 2.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company’s stock valued at $752,000 after buying an additional 339 shares during the last quarter. Finally, KBC Group NV bought a new position in shares of Mirum Pharmaceuticals during the first quarter valued at about $89,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $74.38 on Friday. The stock has a 50-day simple moving average of $64.41 and a two-hundred day simple moving average of $51.87. The firm has a market capitalization of $3.74 billion, a P/E ratio of -61.47 and a beta of 0.92. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $78.10. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.97 and a current ratio of 3.13.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The firm had revenue of $127.79 million during the quarter, compared to the consensus estimate of $107.91 million. During the same quarter in the prior year, the firm earned ($0.52) EPS. The company’s revenue for the quarter was up 64.1% on a year-over-year basis. On average, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Insider Activity at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $58.00, for a total value of $580,000.00. Following the transaction, the senior vice president directly owned 2,426 shares in the company, valued at approximately $140,708. This represents a 80.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Laura Brege sold 17,000 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $74.40, for a total transaction of $1,264,800.00. Following the completion of the transaction, the director owned 15,703 shares in the company, valued at approximately $1,168,303.20. This represents a 51.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 117,619 shares of company stock valued at $7,313,448. 14.36% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on MIRM shares. Stifel Nicolaus set a $89.00 target price on Mirum Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 11th. Evercore ISI raised their target price on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Raymond James Financial reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 7th. JMP Securities set a $81.00 target price on Mirum Pharmaceuticals and gave the stock a “market outperform” rating in a research note on Thursday, August 7th. Finally, HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $74.44.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.